Literature DB >> 17646947

[A method for reassessment of cost-intensive cases in visceral surgery. Results of project by the German Society for Visceral Surgery].

R Lohmann1, O Schäfer, C Graeb, T Becker, E Lopez-Hänninen, S Maas, J M Langrehr.   

Abstract

Since the introduction of diagnosis-related groups (DRGs) many surgical departments report inappropriate reimbursement for complex cases and a shift in costly cases. To evaluate this situation, the German Society for Visceral Surgery inaugurated the present cost calculation project. In three university hospitals for 50 cases each, we depicted possible cost separators and utilized the complete cost calculation data (so-called Paragraph 21 data set) to test these separators. We identified "admission from another hospital", "severe surgically relevant concomitant disease", and "reoperation during the same hospital admission". The last was considered the economically most significant and medically most valid factor and was submitted as a possible modification to the german DRG system. The proposed cost separator "reoperation during the same hospital admission" was introduced into the DRG system after validation and leads to better allocation of reimbursements to complex and costly cases.

Mesh:

Year:  2007        PMID: 17646947     DOI: 10.1007/s00104-007-1375-8

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  1 in total

1.  [Analysis of personnel costs after reorganization of intensive care using calculated diagnosis-related groups comparative data. An investigation at the Charité Berlin].

Authors:  J P Braun; B Schwilk; L Kuntz; M Kastrup; U Frei; D Schmidt; B Behrends; A Schleppers; U Kaisers; C Spies
Journal:  Anaesthesist       Date:  2007-03       Impact factor: 1.041

  1 in total
  1 in total

1.  [Visceral and thoracic surgical interventions in patients over 80 years old. Evaluation of cost coverage].

Authors:  F Löhe; H M Hornung; K-W Jauch; M K Angele
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.